ReviewDiabetes & metabolism journal2025
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning.
Review in Diabetes & metabolism journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.Endocrinology, diabetes & metabolism · 2026Pooled it
- Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice.Frontiers in endocrinology · 2026Guideline
- Trial
- GLP-1 based therapy of obesity and type 2 diabetes.Diabetology international · 2027Review
- Efficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2026Review
- Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.Current obesity reports · 2026Review
- Benzothiazole-Derived Compounds as Potential Drugs for the Treatment of Type 2 Diabetes: A Descriptive Review.International journal of molecular sciences · 2026Review
- Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity:Saudi medical journal · 2026Article
- GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Article
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.Aesthetic plastic surgery · 2026Article
- Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.Diabetes & metabolism journal · 2026Review
- Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation.Obesity pillars · 2026Review
- Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care.The Journal of nutrition · 2026Article
- Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.Journal of obesity & metabolic syndrome · 2026Review
- Glucagon-like Peptide-1 Receptor Agonists and Chronic Pain: Preclinical Antinociceptive Mechanisms, Indirect Metabolic-Functional Effects, and Clinical Considerations-A Narrative Review.Journal of clinical medicine · 2026Review
- The case for primary prevention of obesity in the era of GLP-1 therapies.The Lancet regional health. Europe · 2026Review
- Perceptions, attitudes, and experiences of GLP-1 receptor agonists for weight management in the United Kingdom: a cross-sectional survey study.BMC public health · 2026Article
- GIPR:GCGR co-agonism restores normal weight in obese rodents.Molecular metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded. The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment. Despite the possibility of adverse events, GLP-1 RAs continue to represent a crucial therapeutic modality for metabolic disturbances. This highlights the significance of ongoing research initiatives aimed at optimizing their safe utilization and refining current treatment protocols to improve patient outcomes. This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.